Contract drug manufacturer Patheon (TSX:PTI) has a new chief financial officer, one who is no stranger to North Carolina’s Research Triangle. Stuart Grant was named executive vice president, CFO by the Research Triangle Park-based company. Grant has held finance positions at several public companies, most recently serving as CFO at Durham-based BioCryst Pharmaceuticals (NASDAQ:BCRX). Grant […]
The new cardiovascular drug being developed by Pozen (NASDAQ:POZN) does not yet even have a name, but it now has a manufacturer to produce it once it secures U.S. Food and Drug Administration approval. The Chapel Hill, North Carolina pharmaceutical company has reached a supply agreement with contract drug manufacturer Patheon (TSX:PTI), according to securities […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Contract drug manufacturer Patheon (TSX:PTI) has won two contracts valued at $18 million to make experimental type 2 diabetes drugs for German pharmaceutical company Boehringer Ingelheim. Research Triangle Park, North Carolina-based Patheon provides contract manufacturing for drugs that are commercialized as well as for those still in research and development. Patheon said the two three-year […]
Contract drug manufacturer Patheon (TSX:PTI) is paring back some operations in Europe and Canada as part of a new corporate strategy to review the company’s global footprint and cut costs. Research Triangle Park, North Carolina-based Patheon said that its new strategy will include investing in its pharmaceutical development services business (PDS), which includes manufacturing the […]